Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer beats Q2 estimates with rising oncology sales, new drug launches, and strong Seagen-driven portfolio growth.

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% ...

Pfizer posts strong Q2 earnings and raises EPS outlook, with oncology growth and new drugs offsetting looming headwinds.

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

Oric Pharmaceuticals’ previously announced plan to focus resources on its two most advanced oncology drugs comes with a sting ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

While the drugmaker reaffirmed its 2025 revenue guidance of $61bn to $64bn, it raised its full-year 2025 profit outlook. Pfizer now expects to earn $2.90 to $3.10 per share, compared with its previous ...

Pfizer's oncology pipeline looks promising. The company's newer approvals could make significant progress. And its efforts to ...

Pfizer Inc (NYSE: PFE) saw its shares rise by more than 4% after the company reported strong second-quarter results that ...

Pfizer (NYSE:PFE) stock gains as the company surpasses Q2 2025 expectations with $14.7B revenue and raises its full-year ...